Basic Information


GTO ID GTC3195
Trial ID NCT05566639
Disease Seasonal Influenza | COVID-19
TherapymRNA vaccine
Treatment mRNA-1010
PhasePhase3
Recruitment statusCompleted
TitleA Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older
Year2022
CountryBulgaria|Canada|Denmark|Estonia|Germany|Netherlands|Poland|Spain|China|United Kingdom|United States
Company sponsorModernaTX, Inc.
Other ID(s)mRNA-1010-P302|2022-001638-12
Vector information
Vectorlipid nanoparticle

Clinical Result

Cohort1: mRNA-1010
Administration route intramuscular injection
Dosage mRNA-1010, single dose, on Day 1
Age Adult, Older_Adult
Cohort2: Fluarix Tetra
Administration route intramuscular injection
Dosage Licensed quadrivalent inactivated seasonal influenza vaccine, single dose, on Day 1
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph